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Dexrazoxane for Preventing Anthracycline Cardiotoxicity  
in Children with Solid Tumors
This study attempted to assess the incidence and outcome of anthracycline cardiotoxicity 
and the role of dexrazoxane as a cardioprotectant in childhood solid tumors. The 
dexrazoxane group included 47 patients and the control group of historical cohort included 
42. Dexrazoxane was given in the 10:1 ratio to doxorubicin. Fractional shortening and 
systolic and diastolic left ventricular diameters were used to assess the cardiac function. The 
median follow-ups were 54 months in the dexrazoxane group and 86 months in the 
control group. The mean cumulative doses of doxorubicin were 280.8±83.4 mg/m
2 in the 
dexrazoxane group and 266.1±75.0 mg/m
2 in the control group. The dexrazoxane group 
experienced significantly fewer cardiac events (27.7% vs. 52.4%) and less severe congestive 
heart failure (6.4% vs. 14.3%) than the control group. Thirteen cardiotoxicities including 
one cardiac death and 2 congestive heart failures occurred in the dexrazoxane group, and 
22 cardiotoxicities including 2 cardiac deaths and 4 congestive heart failures, in the control 
group. Five year cardiac event free survival rates were 69.2% in the dexrazoxane group and 
45.8% in the control group (P=0.04). Dexrazoxane reduces the incidence and severity of 
early and late anthracycline cardiotoxicity in childhood solid tumors.
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ORIGINAL ARTICLE
Pediatrics
INTRODUCTION
Anthracyclines play an important role in combination chemo-
therapeutic regimens for both solid tumors and hematological 
malignancies in children (1, 2). However, anthracycline cardio-
toxicity has been a major concern to pediatric oncologists and 
a limiting factor in prescribing anthracyclines (3, 4). The dam-
age of the heart by anthracycline chemotherapy can be divided 
into an early and late cardiotoxicity. Early cardiotoxicity devel-
ops during treatment or in the first year after its completion, 
whereas late cardiotoxicity develops at least one year after ther-
apy in cancer survivors (3, 4).
  Although cumulative anthracyline doses are usually limited 
to 450-500 mg/m
2 (5), a significant proportion of children treat-
ed with anthracycline even at doses less than 300 mg/m
2 have 
evidence of cardiac dysfunction (6-8). Considering that the ma-
jority of long-term survivors of childhood cancers received an 
anthracycline during treatment, and that relatively high doses 
of anthracyclines remain essential to the clinical effectiveness 
of many chemotherapy regimens, cardioprotection from an-
thracycline is important in cancer therapy (3, 7).
  An effective way to avoid the cardiotoxic effect of anthracy-
clines is to prevent cardiac injury during chemotherapy (9). To 
ameliorate the cardiotoxic side effect of anthracyclines, several 
strategies, including limitation of the cumulative dose of anthra-
cyclines, different anthracycline dosage schedules, or different 
cardioprotective agents, have been studied (1, 8, 10). Currently, 
the most effective cardioprotectant for use in children is dexra-
zoxane (10, 11). This compound has been shown to offer a con-
siderable protection from anthracycline cardiotoxicity in clini-
cal studies of adults and children (10, 11). Although the results 
of the dexrazoxane studies in children are promising, evidence 
to make a recommendation for the use of dexrazoxane to pre-
vent anthracycline cardiotoxicity in children is limited (10, 12).
  This study attempted to assess the incidence and outcome of 
anthracycline cardiotoxicity and the role of dexrazoxane as a 
cardioprotectant in children with solid tumors, using serial echo-
cardiography.
MATERIALS AND METHODS
Patients group
Since August 2001, dexrazoxane was introduced as a cardiopro-
tective agent into the patients who had received anthracyclines. 
We enrolled patients who were diagnosed as having solid tumors 
and treated them in our institution with the same chemothera-Choi HS, et al.  •  Dexrazoxane in Childhood Solid Tumors
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peutic regimen from August 2001 to August 2005 (dexrazoxane 
group). Doxorubicin was administered at a dose of 30 mg/m
2 in 
combination with cisplatin 60 mg/m
2, cyclophosphamide 60 
mg/kg, and etoposide 200 mg/m
2 at intervals of 4 weeks with or 
without chest radiation therapy. Autologous peripheral blood 
stem cell transplantation (PBSCT) following high-dose chemo-
therapy consisted with melphalan 210 mg/m
2, etoposide 800 
mg/m
2, and carboplatin 1,600 mg/m
2 was indicated for high risk 
patients. Because it was not feasible to enroll a control group with-
out cardioprotection at the same time, we recruited a historical 
control cohort (control group) treated with the same chemo-
therapy, including doxorubicin without dexrazoxane, in the pe-
riod of January 1995 to July 2001. Supportive treatment, includ-
ing hematopoietic growth factors, antibiotics, and transfusions, 
was given according to the guidelines of our institution without 
change over the period of patient enrollment.
Administration of doxorubicin and dexrazoxane  
Doxorubicin was administered intravenously as a bolus infu-
sion. Dexrazoxane (Cardioxane, Chiron, The Netherlands) was 
administered intravenously 30 min prior to each dose of doxo-
rubicin in the 10:1 ratio dexrazoxane:doxorubicin, as previously 
recommended (13, 14). There was no clinically significant side 
effect associated with dexrazoxane administration. 
Echocardiography
Cardiac function was assessed by echocardiogram in both groups. 
Echocardiographic parameters fractional shortening (FS), and 
systolic and diastolic left ventricular (LV) diameters, were used 
to assess cardiac function, and they were examined by the rec-
ommended standard approach from the M-mode record. 
  Each individual examination was performed by the same 
cardiologist. Echocardiograms were required before the initia-
tion of doxorubicin therapy and performed every 2-3 doses of 
doxorubicin before cumulative dose of doxorubicin reached 
300 mg/m
2, and after then, performed with every dose of doxo-
rubicin administration.
  In the case of decreased FS or increased LV dimension, doxo-
rubicin therapy was discontinued. Echocardiography is also 
performed regularly on a yearly basis after completion of the 
treatment.
Assessment of cardiac toxicity 
A cardiac event was defined as the existence of at least one of 
the following three criteria: 1) increased LV diastolic diameter 
for the age; 2) increased LV systolic diameter for the age; or 3) FS 
less than 28% at any time point of doxorubicin treatment (15). 
For the age-related normal echocardiographic measurement 
range of LV dimension, we referred to ‘the age-related echocar-
diographic measurement standard of normal subjects’ devel-
oped by Henry et al. (16). Subclinical or asymptomatic cardio-
toxicity was diagnosed on the basis of changes in the FS and LV 
diameters, and clinical cardiotoxiticy was based on the presence 
of heart failure symptoms. 
  Severity of heart failure was assessed and classified following 
three levels/grades: 1) death due to congestive heart failure 
(CHF); 2) CHF requiring medication; or 3) subclinical or asymp-
tomatic heart failure. 
  Cardiac toxicity during or within one year after the doxorubi-
cin treatment was defined as early cardiotoxicity and, later than 
that period, defined as late cardiotoxicity. Cardiac event free 
survival was defined as the time from the date of first treatment 
until the date a cardiac event was first noted.
Ethics statement
The study was approved by the Institutional Review Board of 
Seoul National University Hospital (No. 0110-084-006). Since 
all subjects were under 18 yr of age, the subject’s parents gave 
their written informed consent on behalf of their children, and 
the parents were present during the examination.     
Statistical analysis 
The results were presented as mean±standard deviation followed 
by range and median values in parentheses. The statistical anal-
ysis was based on the Student’s t-test and chi-square test. Prob-
abilities of event-free survival and overall survival were estimat-
ed by the method of Kaplan and Meier. The log-rank test was 
used to assess differences between the dexrazoxane group and 
the control group. Logistic-regression analysis was used to iden-
tify covariates associated with cardiotoxicity. A P value less than 
0.05 was considered to be a significant change. The statistical pro-
gram SPSS v15 was used for the purpose of statistical analyses. 
RESULTS
Patient characteristics
The dexrazoxane group included 47 patients (29 males, 18 fe-
males). Their diagnoses were 25 neuroblastoma, 4 peripheral 
primitive neuroectodermal tumors (PPNET), 15 retinoblasto-
ma, and 3 other solid tumors. Three patients with cardiac dys-
function before doxorubicin therapy were excluded from the 
dexrazoxane group. The control group included 42 patients (25 
males, 17 females). Their diagnoses were 40 neuroblastoma and 
2 PPNET. Eleven patients were excluded from the historical co-
hort for the following reasons: one misdiagnosis, 2 incomplete 
records, 3 early withdrawals without echocardiographic evalu-
ations, 3 congenital heart diseases, and 3 cardiac dysfunctions 
before doxorubicin therapy. Patients’ characteristics were de-
scribed in Table 1.
  The median ages of the patients were 24 months (1-168) in the 
dexrazoxane group and 30 months (3-137) in the control group, 
which were not significantly different from each other (P=0.737). Choi HS, et al.  •  Dexrazoxane in Childhood Solid Tumors
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The number of patients received chest radiation therapy were 
14 in the dexrazoxane group and 3 in the control group, which 
was significantly higher in the dexrazoxane group (P=0.007). The 
number of patients who underwent autologous PBSCT was 7 in 
the dexrazoxane group and 11 in the control group, which was 
not significantly different (P=0.966). The median follow-up du-
rations were 54 months (7-93) for the dexrazoxane group and 86 
months (7-158) for the control group, longer in the control group 
(P=0.008). The cumulative doses of doxorubicin were 280.8±83.4 
mg/m
2 (109-428; median 290) in the dexrazoxane group and 
266.1±75.0 mg/m
2 (87-388; median 294) in the control group, 
which were not significantly different (P=0.387) (Table 2).
Table 1. Patients characteristics
Variables  Control group  Dexrazoxane group  P
Number of patients 42 47    
Sex (male/female) 25/17 29/18 0.834 
Age at diagnosis (months) Median 30 (3-127)  Median 24 (1-168) 0.737 
Follow-up duration (months) Median 86 (7-158) Median 54 (7-93) 0.008
Age at last echoCG (months) Median 101 (13-260)  Median 79 (8-222) 0.213
Diagnosis Neuroblastoma 40 Neuroblastoma 25
        Stage II 2    Stage II 1 
       Stage III 14    Stage III 14
       Stage IV 24    Stage IV 10
PPNET 2 PPNET 4 
Retinoblastoma 15
Other solid tumors 3 
Chest RT 3 (7.1%)  14 (29.8%)  0.007
HSCT 11 (26.2%)    7 (14.9%) 0.966 
RT, radiation therapy; HSCT, hematopoietic stem cell transplantation; PPNET, peripheral primitive neuroectodermal tumor.
Table 2. Cumulative dose of doxorubicin 
Variables  Control group (n=42) Dexrazoxane group (n=47) P
Cumulative dose of doxorubicin (mg/m
2) 266.1±75.0 (87-388; median 294) 280.8±83.4 (109-428; median 290) 0.387  
Cumulative dose of doxorubicin (mg/m
2) till cardiac event      272.2±61.3 (120-380; median 299.5)  286.1±66.5 (198-393; median 300) 0.539 
No. of patients with cardiac event
CD DXR ≤100 mg/m
2 0/1 (0%) 0
            ~200 mg/m
2 1/5 (20%) (L1) 1/9 (11.1%) (E1) 0.661
            ~300 mg/m
2 11/18 (61.1%) (E7 L4) 7/17 (41.2%) (E6 L1) 0.245
            >300 mg/m
2 10/18 (55.6%) (E9 L1) 5/21 (23.8%) (E5) 0.020
CD DXR, cumulative dose of doxorubicin; E, early cardiotoxicity; L, late cardiotoxicity.
Doxorubicin cardiotoxicity
In the dexrazoxane group, there were 12 early cardiotoxicities: 
in 7 patients during doxorubicin therapy, in 5 patients less than 
one year after doxorubicin therapy, and one late cardiotoxicity. 
In the control group, there were 16 early cardiotoxicities: in 12 
patients during doxorubicin therapy, 4 patients less than one year 
after doxorubicin therapy, and 6 late cardiotoxicities (Table 3).
  Most of the cardiotoxicity was subclinical and asymptomatic. 
In the dexrazoxane group, there were one cardiac death and 2 
CHF requiring medication. In the control group, there were 2 
cardiac deaths and 4 CHF requiring medication among 22 pa-
tients with cardiotoxicity. 
  Compared with the control group treated with doxorubicin 
alone, the dexrazoxane group treated with doxorubicin and 
dexrazoxane experienced significantly fewer cardiac events 
(52.4% vs. 27.7%, P=0.017) and a lower and less severe incidence 
of CHF (14.3% vs. 6.4%, P=0.049). The incidence of cardiac dys-
function in the disease free survivors was 19.4% (6/31) in the 
dexrazoxane group and 54.5% (12/22) in the control group, 
which showed a significant difference (P=0.03). 
Cardiac event free survivals 
The 5 yr cardiac event free survival rates were 69.2% in the dexra-
zoxane group and 45.8% in the control group, which showed a 
significant difference (P=0.04) (Fig. 1). No case of secondary 
Table 3. Cardiac event 
Variables 
Control group  
(n=42)
Dexrazoxane group 
(n=47)
P
Cardiotoxicity  22 (52.4%)   13 (27.7%)    0.017
   Early
   Late   
16 (38.1%) 
  6 (14.3%)
 12 (25.5%)  
 1 (2.2%)
Severity of cardiotoxicity 
   1) CHF, cause of death 
   2) CHF, requiring medication
   3) Asymptomatic
   Clinical cardiotoxicity 1)+2)
  2
  4
16  
  6 (14.3%)
  1  
  2  
10  
 3 (6.4%)    0.049
Cardiac dysfunction in the 
   disease free survivors 
12/22 (54.5%) 6/31 (19.4%) 0.03
CHF, congestive heart failure.Choi HS, et al.  •  Dexrazoxane in Childhood Solid Tumors
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malignant neoplasm was observed during the follow-up period 
in both groups.
Prognostic factors for cardiotoxicity
Logistic-regression analysis was used to determine which covari-
ates were associated with decreased FS or increased LV dimen-
sion. Covariates were the treatment groups (use of dexrazoxane), 
sex (male vs. female), age (≤2 vs. >2 yr) at diagnosis, chest radia-
tion therapy, hematopoietic stem cell transplantation, and cu-
mulative doses of doxorubicin for early and late cardiotoxicity. 
Only use of dexrazoxane was associated with cardiotoxicity (P= 
0.017). Other covariates did not affect cardiotoxicity significant-
ly. The cumulative doses of doxorubicin till cardiotoxicity were 
286.1±66.5 mg/m
2 (198-393; median 300) in the dexrazoxane 
group and 272.2±61.3 mg/m
2 (120-380; median 299.5) in the 
control group, which were slightly higher in the dexrazoxane 
group, but not significantly different (P=0.539) (Table 2).
DISCUSSION
A clinical dilemma for pediatric oncologists is the need to bal-
ance the efficacy of anthracycline therapy against cardiotoxici-
ty, which causes severe morbidity and reduced quality of life 
(10). Children and adolescents are particularly sensitive to the 
cardiotoxic effects of doxorubicin (5) because cardiac growth is 
impaired and is not able to keep face with the demands placed 
on the heart by normal somatic growth (1, 7). Risk of mortality 
from cardiac-related events is 8-times higher for long-term child-
hood cancer survivors than for the normal population (17).  
  There is a wide variation in the reported frequency of both 
clinical and subclinical cardiotoxicity after anthracycline thera-
py in children (10). Up to 70% of long-term survivors of child-
hood cancer have evidence of cardiac dysfunction, including 
overt CHF (5). The incidence of clinical heart failure has been 
reported to be as high as 16% 0.9 to 4.8 yr after treatment (18) 
and the incidence of subclinical heart failure at a median of 6.4 
yr after treatment more than 57% (19). This variation was par-
tially explained by different definitions of heart failure or differ-
ent ways of assessing cardiac function (2). 
  Anthracycline cardiac damage presumably results from the 
formation of anthracycline-iron complexes within cardiac my-
ocytes (2, 11). These complexes catalyze the formation of iron-
dependent oxygen-free radicals that cause oxidative damage to 
the cells. Dexrazoxane is a bisdioxopiperazine compound act-
ing by inhibiting topoisomerase II, scavenging free radicals, and 
chelating heavy metals (11). Dexrazoxane binds to intracellular 
irons and prevents the formation of free radicals. As a result, the 
myocardial free iron pool is reduced and iron is prevented from 
forming a complex with anthracyclines and causing cellular 
damage (11). 
  Dexrazoxane showed a statistically significant benefit in pre-
venting heart damage, mostly in adults with advanced breast 
cancer (10, 20). No evidence for a difference in response rate or 
survival between the dexrazoxane and the control group was 
found. Dexrazoxane has not yet been introduced as a standard 
prophylaxis of cardiotoxicity in children because there is insuf-
ficient evidence to make a recommendation for the use of dexra-
zoxane in the treatment of pediatric malignancies (10, 12). The 
short-to-medium-term efficacy of dexrazoxane in preventing 
doxorubicin-induced cardiotoxicity was investigated in two ran-
domized trials (5, 13) and several smaller, nonrandomized, con-
trolled trials (9, 21, 22), including one studying different malig-
nancies in children. 
  In this study, dexrazoxane reduced both the incidence and the 
severity of cardiotoxicity. The incidence of dose-limiting cardiac 
events was significantly lower in patients receiving dexrazoxane 
than in dexrazoxane-untreated controls. Thirteen cardiotoxici-
ties (27.7%) occurred in the dexrazoxane group and 22 cardio-
toxicities (52.4%) in the control group. Like other reports, most 
of the cardiotoxicities were subclinical and asymptomatic. Only 
3 patients in the dexrazoxane group (6.4%) and 6 patients in the 
control group (14.3%) had clinical heart failure requiring medi-
cation or leading to death. 
  Despite the need for a high-quality randomized prospective 
study, it is not feasible to enroll large number of homogeneous 
patients during a short period and survey them for more than 
10 yr. Therefore, we recruited historical controls who received 
the same chemotherapeutic regimen, including anthracycline 
without dexrazoxane, to compare with the study population 
treated with anthracycline and dexrazoxane. 
  Cardiotoxicity is reported to be related to the cumulative dose 
of anthracyclines (3, 8, 23) and, above 300 mg/m
2, is known as a 
significant risk factor for decreased cardiac function (24). How-
ever, we could not find a definite dose-dependent increase of 
cardiotoxicity associated with cumulative doses of doxorubicin. 
The cumulative doses of doxorubicin were similar in both the 
dexrazoxane and the control group, even in patients with cardio-
Fig. 1. Kaplan-Meier analysis of cardiac event free survival.  
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toxicities. Early cardiotoxicity seemed to increase with doxoru-
bicin dose in the control group but decrease in the dose above 
300 mg/m
2 in the dexrazoxane group. It can be explained by the 
small numbers of patients and the management policy limiting 
additional doxorubicin in the case of abnormality on echocar-
diography. 
  In addition, the cumulative dose of doxorubicin until a cardi-
ac event was relatively lower than reported and varied from 198 
to 393 mg/m
2 in the dexrazoxane group and 120 to 380 mg/m
2 in 
the control group. This is consistent with the report by Lipshultz 
et al. (8) that found cardiac abnormalities in patients who receiv-
ed lower cumulative doses, even as low as 45 mg/m
2. It suggests 
that there is no “safe dose” free from potential cardiac damage (8).
  In this study, both early and late cardiac dysfunctions were 
defined as cardiac events. That is because most patients with 
early cardiotoxicity had persistent cardiac dysfunctions after-
wards. The decline of FS and enlargement of the LV dimension 
tended to continue, even in the case of transient improvement 
in the course of follow-up. This agrees with the report that the 
degree of cardiac injury identified after the first dose of doxoru-
bicin treatment is related to the likelihood of subsequent echo-
cardiographic abnormalities (25). Cardiac abnormalities were 
persistent and progressive in the patients received anthracy-
clines for acute lymphoblastic leukemia (8).
  All cancer survivors treated with anthracyclines should be 
screened for cardiac damage, symptomatic or not (26). Howev-
er, the best way to monitor cardiac function during and after 
anthracycline treatment is controversial at present. Echocardiog-
raphy is the most commonly used noninvasive method to mea-
sure LV function, but its sensitivity, specificity, and reproducibil-
ity are strongly influenced by interobserver variability (27). Other 
techniques used to determine cardiac injury include multigat-
ed radionuclide scans (MUGA); cardiac-specific biochemical 
markers, such as cardiac troponin T; natriuretic peptide; mag-
netic resonance imaging (MRI); and myocardial tissue biopsy 
(26). Lipshultz et al. (13) reported that their subjects showed 
only subclinical cardiotoxicity with elevated troponin T levels, 
and normal echocardiographic parameters in early phase of the 
treatment; however, in our study, abnormal echocardiographic 
reading was observed in many subjects in the early phase. One 
of the reasons of this difference could be that the ranges of nor-
mal/abnormal echocardiographic parameters used in the field 
were not unified. Therefore, an ideal method for cardiac func-
tion monitoring is necessary.
  In alleviating cardiotoxicity, despite its clear cardioprotective 
effects, dexrazoxane is not routinely used because of concerns 
that it could diminish the anti-tumor activity for the anthracy-
clines or increase other chemotherapy-related toxicities, such 
as hematological or infectious complications (9, 10, 12). In me-
ta-analysis of 9 randomized controlled trials, a lower response 
rate associated with dexrazoxane was not confirmed (10). Only 
for an abnormal white blood cell count at nadir showed signifi-
cant difference compared to the control group (10). In our study, 
it was not feasible to compare overall survival rate which reflect-
ed the long-term efficacy of chemotherapy because of hetero-
geneity of diagnoses in the two groups. However, the number of 
patients who completed scheduled chemotherapy was higher 
in the dexrazoxane group, which reflected that toxicities limit-
ing further chemotherapy were not prominent in the dexrazox-
ane group (data not shown).
  The optimal dose ratio of dexrazoxane/anthracycline for car-
dioprotection has not yet been completely determined. The ratio 
of dexrazoxane to anthracycline dose varied between studies 
and was 6.25:1, 10:1 or 20:1 and all of the doses appeared equal-
ly well tolerated (10).
  The possible higher risk of secondary malignant neoplasm 
associated with dexrazoxane administration in children with 
Hodgkin’s disease (28) was not confirmed in the other random-
ized study in children with high risk acute lymphoblastic leuke-
mia (29). In our study, there was no secondary malignant neo-
plasm in both the dexrazoxane group and the control group. 
  Cost effectiveness should be considered in the use of dexra-
zoxane as a routine management. The added cost of dexrazox-
ane would be justified considering the high cost required by se-
rious sequelae, including congestive heart failure and even mor-
tality from anthracycline-induced cardiomyopathy (30).
  In addition to a cumulative dose of anthracyclines and length 
of post-therapy interval, young and advanced age, female sex, 
and radiation therapy involving the heart are considered to be 
risk factors for cardiotoxicity (17). None of these factors was as-
sociated with cardiotoxicity in this study, which is thought to be 
contributed by the smaller number of samples and limited fol-
low-up periods. Concomitant drugs, including cyclophospha-
mide, rate of anthracycline administration, and type of anthra-
cycline, were not considered in this study, because all patients 
were treated with the same chemotherapeutic regimen. This 
encouraging result, reflecting the benefit of cardioprotection 
needs to exclude the impact of a shorter follow-up time of 54 
months in the dexrazoxane group.
  In conclusion, dexrazoxane reduces the incidence and sever-
ity of early and late cardiotoxicity in children with solid tumors 
receiving doxorubicin chemotherapy. Administration of dexra-
zoxane was well tolerated and no second malignant neoplasm 
was observed during the follow-up period, which might be con-
tributed by the limited follow-up period. This study supports the 
benefit of dexrazoxane as a cardioprotective agent in children 
who are vulnerable to cardiac damage by anthracycline. Evident-
ly, more evidence from randomized controlled study and long-
term follow-up more than 10 yr would be necessary to confirm 
the efficacy of dexrazoxane in children.Choi HS, et al.  •  Dexrazoxane in Childhood Solid Tumors
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